EMA Authorised: Tafinlar (dabrafenib mesilate) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Tafinlar, with the active substance dabrafenib mesilate, for melanoma; the marketing authorization was granted to Novar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TAFINLAR (DABRAFENIB)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Novartis Europharm Limited. Decision date: 26/03/2026